Miraculins Preparing Prostate Dx for FDA Review in 2008, Seeks Development Partners | GenomeWeb
Five years after it first began developing its mass spec-based prostate cancer diagnostic, Miraculins said this week it is getting ready to begin testing it in order to submit it to the US Food and Drug Administration.
 
Last month, the Winnipeg, Manitoba-based company said a validation study confirmed the ability of its pre-prostate-cancer biomarker diagnostic to weed out 23 percent of unnecessary biopsies and identify 93 percent of patients positive for prostate cancer.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.